Morris & Dickson Co., LLC; Order, 34522-34523 [2023-11370]
Download as PDF
34522
Federal Register / Vol. 88, No. 103 / Tuesday, May 30, 2023 / Notices
Judgments related to the PSA are not
subject to Tunney Act review.28
Comments regarding the acquisition
of Sanderson are also not subject to
Tunney Act review in this matter
because the Complaint does not
challenge the Sanderson acquisition.
Rather, the Complaint alleges that the
Settling Defendants’ multi-decade
collaboration on compensation
decisions, sharing of compensation
information, and facilitation of such
conduct was anticompetitive and that
Wayne and Sanderson violated the
Packers and Stockyards Act. Under the
Tunney Act, the court reviews only
whether the proposed remedies address
the violations the United States has
alleged in its complaint.29 Potential
harms arising from that acquisition that
were identified by some public
comments are therefore outside the
permissible scope of review under the
Tunney Act.30
The United States understands that
some of the commenters are advocating
for additional enforcement in the
poultry industry. Parts of the CCAR and
CFFE Comments urge the United States
to continue working to address ‘‘the
antitrust implications of industry data
sharing activities.’’ 31 The Carstensen
Comment focuses almost wholly on
information-sharing; it asks the United
States to continue pursuing other
conspirators, to ‘‘forbid any exchange of
confidential business information of any
kind’’ between the Settling Defendants,
and to ‘‘revisit [its] outdated guidance
on information exchange to emphasize
that such conduct among rivals is likely
ddrumheller on DSK120RN23PROD with NOTICES1
28 Competitive
Impact Statement at 3; see also 15
U.S.C. 12(a). The PSA-related provisions include
changes to compensation and disclosure
requirements for Sanderson and Wayne growers.
29 See Microsoft, 56 F.3d at 1459. Because the
‘‘court’s authority to review the decree depends
entirely on the government’s exercising its
prosecutorial discretion by bringing a case in the
first place,’’ it follows that ‘‘the court is only
authorized to review the decree itself,’’ and not to
‘‘effectively redraft the complaint’’ to inquire into
other matters that the United States did not pursue.
Id. at 1459–60.
30 The United States has statutory authority to
review certain proposed transactions under the
Hart-Scott-Rodino Act, 15 U.S.C. 18a, but contrary
to some of the public comments the United States
does not ‘‘approve’’ transactions. See, e.g., Steves
and Sons, Inc. v. JELD–WEN, Inc., 988 F.3d 690,
713–14 (4th Cir. 2021) (‘‘The Department’s decision
not to pursue the matter isn’t probative as to the
merger’s legality because many factors may
motivate such a decision, including the
Department’s limited resources.’’); see also In re
High Fructose Corn Syrup Antitrust Litig., 295 F.3d
651, 664 (7th Cir. 2002).
31 CFFE Comment at 3 (highlighting the impact of
such information-sharing on poultry growers);
CCAR Comment at 8 (recommending the United
States ‘‘consider the anti-trust implications of such
data sharing arrangements regarding poultry
growers and production details as well’’).
VerDate Sep<11>2014
17:16 May 26, 2023
Jkt 259001
to be unlawful absent specific, limited
justifications.’’ 32
The United States does not contend
that the proposed Final Judgments
resolve all issues in the poultry
industry, but these comments are
outside the scope of Tunney Act review.
They concern conduct not challenged in
the Complaint and thus do not provide
a basis for measuring the relief included
in the proposed Final Judgments.33 The
proposed Final Judgments do address
the claims raised against the Settling
Defendants.
Additionally, the United States
believes the proposed Final Judgments
demonstrate to companies both inside
and outside the poultry industry that
anticompetitive information-sharing
risks significant legal consequences, and
the broad scope of the monitor
contained in the proposed Final
Judgments provides protection against
anticompetitive information-sharing in
contexts other than poultry processing
compensation. The United States takes
the conduct alleged in the Complaint
seriously; the investigation into such
conduct is ongoing and the United
States will pursue additional claims
where the evidence and the law justifies
action. Members of the public are
encouraged to submit information about
potentially unlawful exchanges of
information between competitors to the
Department of Justice Antitrust
Division’s Citizen Complaint Center
(https://www.justice.gov/atr/citizencomplaint-center).
V. Conclusion
After careful consideration of the
public comments, the United States
continues to believe the proposed Final
Judgments provide an effective and
appropriate remedy for the antitrust
violations alleged in the Complaint and
are therefore in the public interest. The
United States will move this Court to
enter the proposed Final Judgments
after the public comments and this
response are published as required by
15 U.S.C. 16(d).
Dated: May 23, 2023.
Respectfully submitted,
FOR PLAINTIFF UNITED STATES OF
AMERICA
lllllllllllllllllllll
Kathleen Simpson Kiernan,
U.S. Department of Justice, Antitrust
Division, Civil Conduct Task Force, 450 Fifth
Street NW, Suite 8600, Washington, DC
20530, Tel: 202–353–3100, Fax: 202–616–
2441, Email: Kathleen.Kiernan@usdoj.gov.
[FR Doc. 2023–11388 Filed 5–26–23; 8:45 am]
BILLING CODE 4410–11–P
32 Carstensen
PO 00000
Frm 00057
Comment at 2.
Fmt 4703
Sfmt 4703
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. 18–31]
Morris & Dickson Co., LLC; Order
On May 19, 2023, I issued and served
on the parties a Decision and Order (the
Decision and Order) revoking, effective
30 days from the date of publication in
the Federal Register, Certificate of
Registration Nos. RM0314790 and
RM0335732 issued to Morris & Dickson,
Co., LLC (Respondent). By motion dated
May 20, 2023, Respondent requested a
stay of the Decision and Order. On May
21, I issued an order soliciting
additional information from Respondent
and asking the Government to respond
to Respondent’s Motion for Stay. On
May 22, both parties responded.
Respondent clarified that it was
requesting a stay of at least 90-to-120
days so that it can renew settlement
negotiations with the Government.
Respondent’s May 22, 2023 Letter re
Motion for Stay, at 1. Respondent also
stated that a stay was necessary to
mitigate the impact on its ‘‘customers,
employees, and other stakeholders,’’
including pharmacies, hospitals, and
patients. Id. at 4–5. The Government
indicated that it opposed any stay
request, but stated that it was ‘‘open to
settlement offers’’ and suggested it was
willing to engage in settlement
negotiations with Respondent.
Government’s Opposition to Motion to
Stay, at 3.
Upon consideration of the entire
record before me, the public interest—
in particular, the potential need for
Respondent’s customers and their
patients to find new suppliers given the
revocation of Respondent’s
registrations—and the possibility for
renewed settlement negotiations, I
hereby order that the May 19, 2023
Decision and Order will be effective on
August 28, 2023—ninety days from the
date of the Decision and Order’s
publication in the Federal Register.
This change is reflected in the
published Decision and Order.
It is so ordered.
Signing Authority
This document of the Drug
Enforcement Administration was signed
on May 23, 2023, by Administrator
Anne Milgram. That document with the
original signature and date is
maintained by DEA. For administrative
purposes only, and in compliance with
requirements of the Office of the Federal
Register, the undersigned DEA Federal
Register Liaison Officer has been
authorized to sign and submit the
E:\FR\FM\30MYN1.SGM
30MYN1
Federal Register / Vol. 88, No. 103 / Tuesday, May 30, 2023 / Notices
document in electronic format for
publication, as an official document of
DEA. This administrative process in no
way alters the legal effect of this
document upon publication in the
Federal Register.
Scott Brinks,
Federal Register Liaison Officer, Drug
Enforcement Administration.
[FR Doc. 2023–11370 Filed 5–26–23; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. 18–31]
Morris & Dickson Co., LLC; Decision
and Order
ddrumheller on DSK120RN23PROD with NOTICES1
On May 2, 2018, the Drug
Enforcement Administration (DEA or
Government), issued an Order to Show
Cause (OSC) and Immediate Suspension
of Registration (ISO) to Morris &
Dickson Co., LLC (Respondent), of
Louisiana. Administrative Law Judge
(ALJ) Exhibit (ALJX) 1, at 1. The OSC
informed Respondent of the immediate
suspension of its Certificates of
Registration Nos. RM0314790 and
RM0335732 (registrations) 1 and
proposed their revocation pursuant to
21 U.S.C. 824(a)(4) and 823(b) because
it alleged that Respondent’s continued
registrations were inconsistent with the
public interest. Id.
Respondent requested a hearing
before a DEA ALJ, which was conducted
from May 13 to May 16, 2019. On
August 29, 2019, the ALJ issued a
Recommended Decision (RD), which
was transmitted to the Agency along
with the administrative record on
November 26, 2019.2 The Agency has
incorporated portions of the ALJ’s RD
herein.
The Government presented a prima
facie case. Respondent ultimately
admitted to and accepted some
responsibility for its failures in
effectively applying its customer due
1 Respondent sought and obtained a temporary
restraining order against enforcement of the ISO.
See ALJX 89, at 7. On May 18, 2018, the DEA
Acting Administrator rescinded the ISO issued on
May 2, 2018. Tr. 12; see Stip. 26.
2 On October 8, 2019, Respondent filed
Exceptions to the Recommended Decision (Resp
Exceptions) and on November 7, 2019, the
Government filed a response to Respondent’s
Exceptions. On January 5, 2022, Respondent filed
a Motion to Reopen the Administrative Record. On
January 14, 2022, the Government filed an
opposition to this motion and on January 21, 2022,
Respondent filed a Reply Memorandum in Support
of its Motion to Reopen the Administrative Record.
The Agency addresses the Exceptions throughout
and the Motion to Reopen at the end of this
Decision.
VerDate Sep<11>2014
17:16 May 26, 2023
Jkt 259001
diligence in assessing orders of
controlled substances, its failures to
implement a suspicious order
monitoring system ‘‘consistent with best
practices for compliance,’’ and its
failures to adequately resolve red flags
on orders that it shipped. See infra
section V. Respondent also admitted
that its three suspicious order reports to
DEA during the relevant time period
were insufficient. Id. Nonetheless,
Respondent presented testimony and
evidence aimed at rebutting the
Government’s case with regard to the
scope of its regulatory noncompliance
during the relevant time period.
After thoroughly reviewing the entire
record, the Agency finds substantial
record evidence that Respondent’s
continued registration is inconsistent
with the public interest in light of the
long-term, egregious failures of
Respondent in its responsibility as a
distributor to maintain effective controls
against diversion of controlled
substances. Furthermore, the Agency
finds that Respondent has failed to
demonstrate that the Agency should
continue to entrust it with its controlled
substance registrations.
I. Summary of the Allegations
1. The OSC primarily alleged that
Respondent failed to maintain effective
controls against diversion when it failed
to report to DEA thousands of unusually
large orders for hydrocodone and
oxycodone, which constituted potential
suspicious orders, and when it shipped
orders to customers without resolving
red flags of diversion or reporting the
orders to DEA in violation of 21 U.S.C.
823(b)(1) and (e)(1) as well as 21 CFR
1301.71(a) and 1301.74(b). OSC, at 2.
Further, the OSC alleged that
Respondent failed to adequately design
and operate a system to alert
Respondent to suspicious orders of
controlled substances and failed to
report the suspicious orders to DEA in
violation of 21 CFR 1301.74(b). Id.
2. The allegations included that, from
January 2014 until April 2018,
Respondent shipped approximately
7,000 unusually large orders of
oxycodone and almost 5,000 unusually
large orders of hydrocodone. OSC, at 5;
Govt Prehearing, at 8. During this time,
Respondent filed a total of only three
suspicious order reports with DEA.
3. Furthermore, the OSC alleged that,
from approximately January 2014 to
April 2018,3 Respondent failed to carry
3 The allegations for three of the exemplar
pharmacies only spanned a subset of this
timeframe: Wellness Pharmacy, January 2014–
December 2017; Wilkinson Family Pharmacy,
January 2014–April 2017; Hephzibah Pharmacy,
April 2017–May 2017. Govt Prehearing, at 3.
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
34523
out its due diligence and suspicious
order monitoring policies and failed to
conduct or failed to document the
resolution of meaningful due diligence
into orders placed by the following
pharmacies: Wallace Drug Company,
Inc.; Bordelon’s Super-Save Pharmacy;
Folse Pharmacy; Pharmacy Specialties
Group, Inc.; Dave’s Pharmacy; the
Wellness Pharmacy, Inc.; Wilkinson
Family Pharmacy; and Hephzibah
Pharmacy, L.L.C. (hereinafter, the
exemplar pharmacies).
II. The Witnesses
A. The Government’s Witnesses
The Government presented its case
through the testimony of six witnesses
and the introduction of 70 exhibits. The
Government’s first witness was the
Acting Section Chief of the
Pharmaceutical Investigation Section of
the DEA (the Section Chief), who
testified generally regarding the
regulatory requirements for distributors.
Tr. 47–87. The Government also
presented testimony from two Diversion
Investigators (DI 1 and DI 2) regarding
the history of the investigation and the
identification of Government exhibits.4
See RD, at 11–12 (citing Tr. 94–101;
144–177). Next, the Government
presented testimony from the Chief of
the Statistical Services Section of DEA,
G.R., who was qualified without
objection as an expert in ‘‘developing
and implementing statistical models
and methods of analyzing large and
complex data sets.’’ RD, at 13 (citing Tr.
192). G.R. testified to the methodology
he employed in analyzing the statistical
data that was used by DEA in its
determination that Respondent had
failed to report suspicious orders.5 RD,
at 12–15 (citing Tr. 187–245). The
Government also presented testimony
from the Group Supervisor of the New
Orleans Field Division (the GS), who
was accepted as an expert in ‘‘the
identification of common red flags
suggestive of an illicit pharmaceutical
operation and as well [as] with respect
to the requirements imposed on DEA
registrants to identify and investigate
4 The Government presented testimony from a
third Diversion Investigator (DI 3) to rebut the
testimony of Respondent’s witness, however, the
Agency agrees with the RD that the testimony of DI
3 was not essential to the case and is therefore not
including it herein. RD, at 20.
5 G.R. testified that he had corrected DEA’s
admitted error in the calculations in the OSC,
which applied a Three Interquartile Range (IQR) to
the median of the data set, or the 50th percentile,
instead of the 75th percentile, and as a result,
produced a larger group of outliers. Tr. 204, 208–
09. G.R. further acknowledged that the error was
identified by Respondent’s expert. Tr. 218.
E:\FR\FM\30MYN1.SGM
30MYN1
Agencies
[Federal Register Volume 88, Number 103 (Tuesday, May 30, 2023)]
[Notices]
[Pages 34522-34523]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-11370]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. 18-31]
Morris & Dickson Co., LLC; Order
On May 19, 2023, I issued and served on the parties a Decision and
Order (the Decision and Order) revoking, effective 30 days from the
date of publication in the Federal Register, Certificate of
Registration Nos. RM0314790 and RM0335732 issued to Morris & Dickson,
Co., LLC (Respondent). By motion dated May 20, 2023, Respondent
requested a stay of the Decision and Order. On May 21, I issued an
order soliciting additional information from Respondent and asking the
Government to respond to Respondent's Motion for Stay. On May 22, both
parties responded. Respondent clarified that it was requesting a stay
of at least 90-to-120 days so that it can renew settlement negotiations
with the Government. Respondent's May 22, 2023 Letter re Motion for
Stay, at 1. Respondent also stated that a stay was necessary to
mitigate the impact on its ``customers, employees, and other
stakeholders,'' including pharmacies, hospitals, and patients. Id. at
4-5. The Government indicated that it opposed any stay request, but
stated that it was ``open to settlement offers'' and suggested it was
willing to engage in settlement negotiations with Respondent.
Government's Opposition to Motion to Stay, at 3.
Upon consideration of the entire record before me, the public
interest--in particular, the potential need for Respondent's customers
and their patients to find new suppliers given the revocation of
Respondent's registrations--and the possibility for renewed settlement
negotiations, I hereby order that the May 19, 2023 Decision and Order
will be effective on August 28, 2023--ninety days from the date of the
Decision and Order's publication in the Federal Register. This change
is reflected in the published Decision and Order.
It is so ordered.
Signing Authority
This document of the Drug Enforcement Administration was signed on
May 23, 2023, by Administrator Anne Milgram. That document with the
original signature and date is maintained by DEA. For administrative
purposes only, and in compliance with requirements of the Office of the
Federal Register, the undersigned DEA Federal Register Liaison Officer
has been authorized to sign and submit the
[[Page 34523]]
document in electronic format for publication, as an official document
of DEA. This administrative process in no way alters the legal effect
of this document upon publication in the Federal Register.
Scott Brinks,
Federal Register Liaison Officer, Drug Enforcement Administration.
[FR Doc. 2023-11370 Filed 5-26-23; 8:45 am]
BILLING CODE 4410-09-P